Investor
Fairmount Funds Management LLC
CIK 0001802528 · filed 2026-05-15 · SEC filing
13F book
$1.38B
Positions
12
1 new · 2 sold
Largest name
16.3%
Galecto Inc · DMRA
Est. mark
$221M
Price effect on 11 names still held. Flow −$150.4M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Galecto Inc | DMRA | 8.71M | $225.7M | 16.3% | — | New |
| Dianthus Therapeutics Inc | — | 2.54M | $212.9M | 15.4% | $91.3M | Added$124.8M |
| Cogent Biosciences, Inc. | COGT | 5.5M | $211.8M | 15.3% | $16.3M | Cut−$108M |
| Spyre Therapeutics, Inc. | SYRE | 4.02M | $202.7M | 14.6% | $71M | Held |
| Oruka Therapeutics, Inc. | ORKA | 3.71M | $181.7M | 13.1% | $69.4M | Held |
| Viridian Therapeutics Inc | — | 3.91M | $76.6M | 5.5% | −$45.3M | Held |
| Enliven Therapeutics, Inc. | ELVN | 1.86M | $72.7M | 5.3% | $44.2M | Cut$15.6M |
| Jade Biosciences, Inc. | JBIO | 4.55M | $64M | 4.6% | −$6.28M | Held |
| Crescent Biopharma, Inc. | CBIO | 2.75M | $50.5M | 3.6% | $17.9M | Held |
| Zenas BioPharma, Inc. | ZBIO | 2.36M | $46.1M | 3.3% | −$37M | Added−$34.1M |
| Apogee Therapeutics, Inc. | APGE | 298.6K | $25.1M | 1.8% | $2.6M | Cut−$129.5M |
| Inhibikase Therapeutics, Inc. | IKT | 8.63M | $14.5M | 1.0% | −$3.19M | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.